MedCAC Supports Some PGx Test Regimens, But Calls For Overall Better Data
This article was originally published in The Gray Sheet
Executive Summary
There is enough strong evidence to show that a select few pharmacogenomic (PGx) tests can be applied in a manner that positively affects patient outcomes, members of a CMS advisory panel concluded Jan. 27
You may also be interested in...
CMS Director To Diagnostics Industry: Prove Your Cancer Tests Work
“Why are insurers so reluctant to get enthusiastic and really embrace molecular diagnostics?” asked the director of CMS’ coverage and analysis group at a recent cancer diagnostics symposium. “Because half the time we have no idea what on earth we’re paying for.”
CMS Will Weigh Three New Tech Assessments On Genetic Testing For Cancer
Two of the assessments are intended to inform an upcoming Medicare Evidence Development and Coverage Advisory Committee meeting.
CMS Will Weigh Three New Tech Assessments On Genetic Testing For Cancer
Two of the assessments are intended to inform an upcoming Medicare Evidence Development and Coverage Advisory Committee meeting.